Table 1.

Cases used for study and p73 immunostaining

					% Nuclear		% Cytoplasm
Case	Age	M/F	PMI (h)	p73 level	CA3	CA1	CA3	CA1	Braak stage
Control 1	82	F	4	++	13	25	96	76	I
Control 2	81	M	6	+	16	16	93	42	I
Control 3	85	M	4.5	++	30	22	96	69	I
Control 4	74	F	4.5	++	23	22	74	62	I
Control 5	70	F	5	+	14	19	60	66	III
Control 6	59	F	6	+	5	7	61	71	I
Control 7	82	F	4	+	7	5	97	72	I
Control 8	59	F	6	+	7	12	77	82	I
AD 1	74	F	4.5	++	15	26	59	37	II
AD 2	84	F	3.5	++	25	21	83	49	III
AD 3	85	M	4	+	26	25	75	48	III
AD 4	93	F	5	++	35	27	76	64	III
AD 5	85	F	3	++	27	27	86	62	IV
AD 6	80	M	5	++	34	25	91	52	V
AD 7	85	M	4	+++	14	17	92	89	III
AD 8	81	M	4.5	+++	22	27	75	77	VI
AD 9	81	F	3	+++	31	35	70	59	VI
AD 10	82	M	4	+++	29	25	78	68	V
AD 11	81	M	2.5	+++	13	13	80	54	VI
AD 12	72	F	3.5	+++	28	22	82	55	VI
AD 13	69	F	5	++	31	35	95	59	IV
AD 14	78	M	4	++	50	46	84	69	VI
AD 15	83	F	4.5	+++	32	32	85	80	VI
AD 16	93	M	4.5	+++	12	16	74	55	VI

M, male; F, female; PMI, post-mortem interval; AD, Alzheimer disease. The abundance of p73 immunoreactivity was scored in a four-step scale with (−) corresponding to no immunoreactivity; (+) being weak immunoreactivity; (++) being moderate immunoreactivity; and (+++) being strong immunoreactivity of neurones by visual qualitative analysis of hippocampal sections at × 200 magnification by two independent scorers. Nuclear and cytoplasmic p73 immunoreactivity in both CA1 and CA3 pyramidal neurones was determined as described in the section ‘Materials and methods’. Braak staging is noted for each case.